Eton Pharmaceuticals, Inc. - 8-K Filing

Eton Pharmaceuticals reports Q3 2026 revenue of $57.9 million, up 158% YoY, and raises full-year 2026 guidance. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and ExhibitsExhibit 99)

SEC EDGAR ·

Tickers: $ETON

Read the full article at SEC EDGAR

More Regulatory news